2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.
Antirheumatic Agents
/ therapeutic use
Autoimmune Diseases
/ drug therapy
Bacterial Infections
/ prevention & control
Family Characteristics
Hepatitis A
/ prevention & control
Hepatitis A Vaccines
/ therapeutic use
Hepatitis B
/ prevention & control
Hepatitis B Vaccines
/ therapeutic use
Herpes Zoster
/ prevention & control
Herpes Zoster Vaccine
/ therapeutic use
Humans
Influenza Vaccines
/ therapeutic use
Influenza, Human
/ prevention & control
Papillomavirus Infections
/ prevention & control
Papillomavirus Vaccines
/ therapeutic use
Pneumococcal Infections
/ prevention & control
Pneumococcal Vaccines
/ therapeutic use
Rheumatic Diseases
/ drug therapy
Tetanus
/ prevention & control
Tetanus Toxoid
/ therapeutic use
Vaccines
/ therapeutic use
Vaccines, Attenuated
/ therapeutic use
Virus Diseases
/ prevention & control
autoimmune diseases
infections
vaccination
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
12
06
2019
revised:
19
07
2019
accepted:
22
07
2019
pubmed:
16
8
2019
medline:
21
4
2020
entrez:
16
8
2019
Statut:
ppublish
Résumé
To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.
Identifiants
pubmed: 31413005
pii: annrheumdis-2019-215882
doi: 10.1136/annrheumdis-2019-215882
doi:
Substances chimiques
Antirheumatic Agents
0
Hepatitis A Vaccines
0
Hepatitis B Vaccines
0
Herpes Zoster Vaccine
0
Influenza Vaccines
0
Papillomavirus Vaccines
0
Pneumococcal Vaccines
0
Tetanus Toxoid
0
Vaccines
0
Vaccines, Attenuated
0
Types de publication
Consensus Development Conference
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-52Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.